Prevalence of hepatitis B co-infection and response to antiretroviral therapy among HIV-infected patients in Tanzania

AIDS

Volumn 27, Issue 6, 2013, Pages 919-927

  Hawkins, Claudia ^a,b   Christian, Beatrice ^b   Ye, Jitao ^c   Nagu, Tumaini ^d   Aris, Eric ^b,d   Chalamilla, Guerino ^b,c   Spiegelman, Donna ^c   Mugusi, Ferdinand ^d   Mehta, Saraubh ^e   Fawzi, Wafaie ^b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MANAGEMENT AND DEVELOPMENT FOR HEALTH   (Tanzania)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^e Department of Obstetrics Gynecology   (United States)

Author keywords

Antiretrovirals; Chronic hepatitis B; HIV

Indexed keywords

ALANINE AMINOTRANSFERASE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE SEVERITY; FEMALE; HEPATITIS B; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; ORTHOHEPADNAVIRUS; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX RATIO; TANZANIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URBAN AREA;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COINFECTION; FEMALE; HEPATITIS B; HIV INFECTIONS; HUMANS; MALE; SURVIVAL ANALYSIS; TANZANIA; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84876406805     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835cb9c8     Document Type: Article

References (38)

1. Barth RE, Huijgen Q, Taljaard J, Hoepelman AI. Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and metaanalysis. Int J Infect Dis 2010; 14:e1024-e1031.
2. Sheng WH, Chen MY, Hsieh SM, Hsiao CF, Wang JT, Hung CC, et al. Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. Clin Infect Dis 2004; 38:1471- 1477.
3. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006; 44:S65-70.
4. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
5. Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, et al. Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24:1537-1548.
6. Falade-Nwulia O, Seaberg EC, Rinaldo CR, Badri S, Witt M, Thio CL. Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection. Clin Infect Dis 2012; 55:507-513.
7. Lincoln D, Petoumenos K, Dore GJ. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med 2003; 4:241-249.
8. De Luca A, Bugarini R, Lepri AC, Puoti M, Girardi E, Antinori A, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002; 162:2125-2132.
9. Hoffmann CJ, Seaberg EC, Young S, Witt MD, D'Acunto K, Phair J, et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS 2009; 23:1881-1889.
10. Hoffmann CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, Chaisson RE, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008; 47:1479-1485.
11. National Guidelines for the Management of HIV and AIDS, National AIDS Control Programme (NACP), Third Edition, 2008.
12. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach (2006 revision) http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf [Accessed 5 May 2012].
13. Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007; 21:1301-1308.
14. AIDS Clinical Trials Group. Table for grading severity of adult adverse experiences. Rockville, MD: National Institutes of Allergy and Infectious Diseases, Division of AIDS; 1992.
15. Ox DR. Regression models and life-tables. J Roy Stat Soc Ser B 1972; 34:187-220.
16. Miettinen OS. Theoretical epidemiology: principles of occurrence research in medicine. New York: Wiley; 1985.
17. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73:13-22.
18. Govindarajulu US, Spiegelman D, Thurston SW, Ganguli B, Eisen EA. Comparing smoothing techniques in Cox models for exposure-response relationships. Stat Med 2007; 26:3735- 3752.
19. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989; 8:551-561.
20. Idoko J, Meloni S, Muazu M, Nimzing L, Badung B, Hawkins C, et al. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis 2009; 49:1268-1273.
21. Moore E, Beadsworth MB, Chaponda M, Mhango B, Faragher B, Njala J, et al. Favourable one-year ART outcomes in adult Malawians with hepatitis B and C co-infection. J Infect 2010; 61:155-163.
22. Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004; 18:1169-1177.
23. Sagoe KW, Agyei AA, Ziga F, Lartey M, Adiku TK, Seshi M, et al. Prevalence and impact of hepatitis B and C virus co-infections in antiretroviral treatment naive patients with HIV infection at a major treatment center in Ghana. J Med Virol 2012; 84: 6-10.
24. Lawn SD, Little F, Bekker LG, Kaplan R, Campbel E, Orrell C, Wood R. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 2009; 23:335-342.
25. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Muñoz A, Thomas DL, Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-1926.
26. Salmon-Ceron D, Rosenthal E, Lewden C, Bouteloup V, May T, Burty C, et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national Mortalité 2005 study. J Hepatol 2009; 50:736-745.
27. th Conference on Retroviruses and Opportunistic Infections, Paper #286.
28. Mbougua JB, Laurent C, Kouanfack C, Bourgeois A, Ciaffi L, Calmy A, et al. Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. BMC Public Health 2010; 10:105.
29. Law WP, Dore GJ, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS 2003; 17:2191-2199.
30. den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, et al. Hepatitis B and C virus coinfection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14:2895-2902.
31. Price JC, Thio CL. Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol 2010; 8:1002-1012.
32. Bisceglie AM, Maskew M, Schulze D. HIV-HBV co-infection among South African patients receiving antiretroviral therapy. Antiviral Ther 2010; 15:499-503.
33. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al., EuroSIDA Group. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:593-601.
34. Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, Petcharapirat P, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology 2008; 48:1062-1069.
35. Matthews GV, Seaberg E, Dore GJ, Bowden S, Lewin SR, Sasadeusz J. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine experienced HIV/HBV coinfected individuals. AIDS 2009; 23:1707-1715.
36. Lin CL, Kao JH. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci 2008; 15:137-145.
37. Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000; 46:420-426.
38. Chalamilla G, Hawkins C, Okuma J, Spiegelman D, Aveika A, Christian B, et al. Mortality and treatment failure among HIV-infected adults in Dar Es Salaam, Tanzania. J Int Assoc Physicians AIDS Care (Chic). 2011 [Epub 2011/06/16].